Global Leading Market Research Publisher QYResearch announces the release of its latest report “Genetic Engineering Plant Genomics – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Genetic Engineering Plant Genomics market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Genetic Engineering Plant Genomics was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.
Genetic engineering plant genomics refer to the process of development of new plant lines with enhanced genotypic characteristics by crossing two or more plants with the purpose of producing an offspring that shares the required traits of the parent plants. The aim of the method is to characterize, sequence and study of genetic compositions, functions and networks of entire plant genome. The technological advancement is emerging with the increasing demand for better-quality crops.
For seed developers, agricultural biotechnology firms, and crop breeders, the core challenges are shortening trait development timelines and navigating diverging global regulatory frameworks for genome editing versus transgenic GMOs. Genetic engineering plant genomics encompasses both traditional molecular marker-assisted selection (MAS) and advanced genome editing (CRISPR-Cas9, base editing, prime editing). Recent industry data (ISAAA, January 2026) confirms that over 140 genome-edited plant products have been commercialized or are in advanced regulatory review globally—up from just 25 in 2020—with the majority targeting drought tolerance, disease resistance, and improved nutrient profiles. The market is shifting from commodity traits (herbicide tolerance) toward climate-adaptive and quality traits (non-browning mushrooms, high-oleic soybeans, waxy corn).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984727/genetic-engineering-plant-genomics
The Genetic Engineering Plant Genomics market is segmented as below:
Eurofins Scientific, Illumina Inc, NRGene, Neogen Corporation, Agilent, LC Sciences, LLC, Traitgenetics GmbH, Keygene, Novogene Co. Ltd, GeneWiz, BGI, Genotypic Technology, ADAMA, Bayer AG, UPL, Corteva, Nufarm, DuPont, Syngenta AG, VILMORIN & CIE, SUNTORY HOLDINGS LIMITED
Segment by Type
- Molecular Engineering (marker-assisted selection, quantitative trait loci mapping, genomic selection)
- Genetic Engineering and Genome Editing (CRISPR-Cas9, TALENs, zinc-finger nucleases, base editing)
- Others (RNA interference, cisgenesis, synthetic biology for plant pathways)
Segment by Application
- Cereals and Grains (wheat, rice, maize, barley, sorghum)
- Oilseeds and Pulses (soybean, canola, sunflower, chickpea, cowpea)
- Fruits and Vegetables (tomato, potato, apple, citrus, lettuce)
- Sugar Crops (sugarcane, sugar beet)
- Ornamentals (petunia, rose, chrysanthemum, orchids)
- Alfalfa (forage quality, reduced lignin)
1. Molecular Engineering vs. Genome Editing: Mature Tools vs. Disruptive Innovation
A critical industry distinction: molecular engineering (marker-assisted selection, genomic selection) accelerates traditional breeding by using DNA markers to predict trait inheritance—but does not create novel alleles. This segment is mature, with widespread adoption in public and private breeding programs. Molecular engineering typically shortens breeding cycles from 8–12 years to 4–7 years, at relatively low regulatory burden (most products are not considered GMOs).
Genetic engineering and genome editing represents the growth engine. Genome editing (especially CRISPR-Cas9) introduces precise, targeted changes without necessarily incorporating foreign DNA—a distinction that has led to divergent global policies. A February 2026 ruling by Japan’s Ministry of Agriculture classified genome-edited crops with no foreign DNA as “non-GMO,” accelerating commercialization. Japan now leads in approved genome-edited produce (high-GABA tomato, pufferfish-safe soybean, fast-growing porgy fish), with field trials expanding to wheat and rice in 2026.
Exclusive observation from Q1 2026 service provider surveys: Contract research organizations (CROs) report that genome editing revenue grew 47% year-over-year (2025 vs. 2024), while molecular engineering grew 11%. However, molecular engineering remains essential for validating editing outcomes—combining CRISPR multiplexing with genomic selection predictive models (“CRISPR-GS”) is emerging as a premium service offering.
2. Application Deep Dive: Cereals and Grains Lead Volume, Fruits and Vegetables Lead Regulatory Innovation
Cereals and Grains account for approximately 55% of genetic engineering plant genomics R&D spending. The driver: feeding a growing population on shrinking arable land requires step-change yield improvements beyond conventional breeding. A major industry milestone—in January 2026, Chinese regulators granted safety certificates for CRISPR-edited wheat with 30% higher fiber content and reduced gluten immunogenicity (for celiac-friendly products). This follows the 2024 approval of genome-edited soybeans with high oleic acid in the US. The global pipeline for genome-edited cereals now exceeds 110 events (Cornell GES Database, March 2026).
Fruits and Vegetables represent the fastest-growing commercial segment for genome editing, driven by consumer-facing traits (non-browning, seedless, extended shelf life). The market inflection was Japan’s 2021 approval of CRISPR-edited tomato (Sicilian Rouge High GABA), followed by U.S. approval of non-browning mushrooms (Agaricus bisporus) and high-yield determinate tomato (cv. “Tomelo”). In December 2025, the UK’s Genetic Technology (Precision Breeding) Act came into full force, creating a streamlined pathway for genome-edited plants not containing foreign DNA. Four UK applications for genome-edited lettuce (increased vitamin C) and field pea (lodging resistance) were submitted in Q1 2026.
Ornamentals—often overlooked—is a quiet but lucrative segment. SUNTORY HOLDINGS LIMITED (Japan) has commercially deployed genome-edited petunias and carnations with novel flower colors and extended vase life, bypassing GM regulations in export markets under the “non-transgenic editing” classification. Margins in ornamentals can exceed 60%, compared to 20–30% for commodity crops.
3. Technology-Policy Interface: Off-Target Analysis, Delivery Vectors, and Regulatory Divergence
A persistent technical hurdle for genome editing: off-target mutations. Even CRISPR-Cas9 can introduce unintended edits at sequences similar to the target. Whole-genome sequencing of edited lines adds 5,000–5,000–15,000 per event—significant for smaller breeding programs. However, new high-fidelity Cas9 variants (e.g., eSpCas9(1.1), SpCas9-HF1) reduce off-target activity by 50–90%, while prime editing (Cas9 nickase fused to reverse transcriptase) offers even greater precision. Molecular engineering tools, particularly whole-genome sequencing-based background selection, are now routinely paired with genome editing to certify “clean” events.
Regulatory divergence (exclusive analysis): As of April 2026, three global frameworks exist:
- Trait-based permissive (USA, Japan, Australia, UK, Argentina, Brazil): Genome-edited plants without foreign DNA are regulated similarly to conventional breeding.
- Process-based restrictive (EU, New Zealand): Any genome editing is considered GMO, requiring lengthy risk assessment. This has driven European plant genomics companies to relocate R&D or license results from permissive jurisdictions.
- Hybrid (China, India, Canada): Product-specific, with expedited pathways for edits mimicking natural variation.
For genetic engineering plant genomics service providers, this fragmentation increases compliance costs and incentivizes multi-jurisdictional event characterization.
Policy update (March 2026): The European Commission announced a long-awaited proposal for “New Genomic Techniques” (NGTs), classifying genome-edited plants into two categories: Category 1 (edits equivalent to conventional breeding—streamlined notification) and Category 2 (transgenic or complex edits—full GMO assessment). Industry welcomes the differentiation but estimates 18–24 months for legislative finalization. Meanwhile, EU-based plant breeders continue to use regulatory havens for proof-of-concept.
4. User Case Studies (Last 6 Months, January – June 2026)
Case A – Public breeding program, Australia (CSIRO, wheat heat tolerance): Using CRISPR-Cas9 genome editing, researchers knocked out two genes (TaHRC and TaHsfA2e) associated with heat stress sensitivity. In January 2026 field trials in New South Wales (38°C flowering period), edited lines showed 31% higher grain set compared to wild-type. The project used molecular engineering (KASP markers for selection) to accelerate line fixation, reducing backcrossing from four generations to two. Regulatory pathway: Australia’s Gene Technology Regulations exempt SDN-1 (small deletions) edits, enabling potential commercialization by 2028.
Case B – Ag-biotech SME, USA (potato late blight resistance): A mid-sized seed company employed genome editing to insert three resistance genes (Rpi-vnt1, Rpi-blb2, Rpi-sto1) into a commercial potato variety (cv. Russet Burbank) using Agrobacterium-mediated transformation—a genetic engineering approach, not editing. However, the company used molecular engineering (high-density SNP arrays) to select transformants with intact genomic background and minimal vector backbone. By March 2026, two events with durable resistance were advanced to field trials. Total R&D cost: $2.7 million—40% lower than historical averages due to improved molecular screening.
Case C – Seed company, India (soybean pod borer resistance): Collaborating with BGI and Genotypic Technology, the company developed a genome-edited soybean with gene knockouts in two susceptibility genes (GmSPL12 and GmSPL9), conferring tolerance to Helicoverpa armigera. Field trials (January–April 2026, Maharashtra) showed 52% less pod damage compared to control, with no yield penalty. Regulatory status: India’s 2022 GEAC guidelines treat SDN-1 edits (small deletions) as non-GMO—an expedited pathway. Target market entry: 2028.
5. Industry Layering: Full-Service CROs vs. Platform Technology Specialists
A crucial segmentation lens: full-service CROs (Eurofins Scientific, Novogene, BGI, Genotypic Technology) offer end-to-end genetic engineering plant genomics—from DNA extraction and sequencing to genome editing delivery and event genotyping. Their competitive advantage is scale: BGI’s plant sequencing capacity exceeds 1,000 whole genomes/month. Platform technology specialists (NRGene, Keygene, Traitgenetics GmbH) focus on proprietary analytics—e.g., NRGene’s DeNovoMAGIC for complex polyploid assemblies, Keygene’s KeyPoint for high-throughput genotyping. These firms license software and markers, partnering with CROs for wet-lab execution.
Forward-looking observation (exclusive): By 2028, we anticipate convergence of genetic engineering and molecular engineering in “speed breeding” platforms. Combining CRISPR multiplexing with genomic selection and doubled-haploid technology, a pilot facility in the Netherlands (Keygene + Wageningen University) reduced spring wheat trait introgression from 8 generations to 2.5 generations—equating to 3 years instead of 9. Commercial service launch is expected by Q3 2027, priced at 250,000–250,000–400,000 per trait stack, targeting global breeding companies.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp








